Saliogen Therapeutics, Inc.

CAMBRIDGE, MA · Founded 2020 · CIK 0001845309 · Biotech · Defunct

Genetic medicines for salivary gland dysfunction

saliogen.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$94M
2 Form D · Dec 2021
58 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$20,000,000
Private capital raisedForm D · SEC$74,099,666
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1443ACUREX THERAPEUTICS CORPORATION——
1444Werewolf Therapeutics, Inc.—$104M
1445TRAILHEAD BIOSYSTEMS, INC.—$30M
1446Saliogen Therapeutics, Inc.—$94M
1447BRAINSTORM THERAPEUTICS, INC.——
1448Peptilogics—$41M
1449Thetis Pharmaceuticals LLC—$14M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 5 related persons
  • Craig GordonDirector
  • Joseph HigginsDirector · Executive Officer
  • Sukumar NagendranDirector
  • Sean StalfortDirector
  • Raymond TabibiazarDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.